Federal Legalization Tax Revenue: Projections, Models, and Economic Impact

Executive Summary

Federal cannabis legalization combined with state-level adoption could generate $111 billion in tax revenue over ten years, according to a 2026 Yale University analysis that represents the most comprehensive fiscal projection to date. The study, published by Yale's Program on Addiction Medicine, models scenarios ranging from federal rescheduling to full legalization across all 50 states, with revenue estimates varying dramatically based on tax structure, enforcement mechanisms, and state participation rates. At the federal level alone, a 15% excise tax on cannabis sales could produce approximately $43 billion over the decade, while state and local taxes would contribute the remaining $68 billion under a full-legalization scenario. The projections arrive as Congress debates multiple legalization bills and the Drug Enforcement Administration continues its rescheduling review initiated in 2023. For investors, operators, and policymakers, these figures underscore the fiscal stakes of federal cannabis policy—revenue that could fund everything from addiction treatment programs to infrastructure projects, while simultaneously reshaping the competitive landscape for multi-state operators currently navigating 280E tax burdens and limited banking access.

Why Federal Cannabis Tax Revenue Matters

The $111 billion revenue projection affects federal budget planning, state fiscal policy, 12,000+ licensed cannabis businesses, and approximately 55 million American cannabis consumers. Unlike state-level legalization, which has generated $15.5 billion cumulatively since Colorado's 2014 market launch, federal legalization would unlock nationwide banking access, interstate commerce, and standardized tax collection mechanisms that currently don't exist. The stakeholder universe spans multiple sectors. The federal government faces annual budget deficits exceeding $1.5 trillion, making new revenue streams politically attractive to both deficit hawks and social program advocates. State governments in the 24 adult-use jurisdictions already collect cannabis taxes ranging from 6% in Missouri to 37% combined state-local rates in California, but federal prohibition prevents them from depositing proceeds in federally insured banks without risk. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries currently pay effective tax rates exceeding 70% due to Internal Revenue Code Section 280E, which disallows business deductions for Schedule I substances—federal legalization would immediately restore normal tax treatment and improve margins by 30-40 percentage points. Patients represent another critical constituency. Medical cannabis users in 38 states pay sales taxes on medicine that would be exempt if cannabis were federally recognized as a legitimate pharmaceutical. The Yale study estimates that 4.3 million medical patients spend an average of $2,400 annually on cannabis, generating approximately $1.5 billion in annual state tax revenue that could be redirected to treatment access programs under reformed federal policy. The scale of potential revenue also shapes international competitiveness. Canada's federal cannabis excise tax generated CAD $395 million in fiscal year 2023-2024, approximately USD $290 million, from a population one-ninth the size of the United States. Proportional scaling suggests U.S. federal excise taxes alone could reach $2.6 billion annually, though the Yale model projects more conservative figures of $4.3 billion annually by year ten, accounting for market maturation and price compression.

Background and History of Federal Cannabis Tax Policy

The United States taxed cannabis federally from 1937 to 1970 under the Marihuana Tax Act before prohibition replaced taxation as the primary control mechanism.

The Marihuana Tax Act of 1937

Congress passed the Marihuana Tax Act on August 2, 1937, imposing a $1-per-ounce tax on cannabis transfers for medical and industrial use, and a prohibitive $100-per-ounce tax on recreational transfers. The legislation, championed by Federal Bureau of Narcotics Commissioner Harry Anslinger, generated minimal revenue—approximately $31,000 in its first year—but created a regulatory framework requiring extensive record-keeping that effectively criminalized non-compliance. The Supreme Court upheld the tax in United States v. Sanchez (1950), ruling that the registration requirements did not violate Fifth Amendment protections against self-incrimination. The Act remained in effect until 1970, when the Controlled Substances Act replaced taxation with outright prohibition.

The Controlled Substances Act and Schedule I Classification

President Richard Nixon signed the Controlled Substances Act into law on October 27, 1970, as Title II of the Comprehensive Drug Abuse Prevention and Control Act. The legislation created five schedules of controlled substances, with Schedule I reserved for drugs with "no currently accepted medical use" and "high potential for abuse." The Drug Enforcement Administration placed cannabis in Schedule I on an interim basis in 1971, a classification that has remained unchanged for 55 years despite multiple petitions for rescheduling. Schedule I status eliminated any federal taxation framework for cannabis, as the substance became entirely illegal under federal law.

State-Level Legalization and Tax Revenue Generation

Colorado and Washington became the first states to legalize adult-use cannabis via ballot initiatives on November 6, 2012, with retail sales commencing in 2014. Colorado's Amendment 64 established a 15% excise tax on wholesale transfers and a 15% retail sales tax, generating $69 million in the first fiscal year. By 2023, Colorado had collected $2.1 billion in cumulative cannabis tax revenue, funding school construction, substance abuse programs, and law enforcement training. Washington's Initiative 502 imposed a 37% excise tax at the retail level, later consolidated to 37% after eliminating producer and processor taxes in 2015. The state collected $559 million in fiscal year 2023, with revenues allocated to healthcare, substance abuse prevention, and the general fund. California's Proposition 64, approved November 8, 2016, created a $9.65-per-ounce cultivation tax and a 15% excise tax, generating $1.29 billion in fiscal year 2022-2023 despite widespread illicit market competition. As of August 2026, 24 states plus the District of Columbia, Guam, and the Northern Mariana Islands have legalized adult-use cannabis, collectively generating approximately $15.5 billion in cumulative tax revenue since 2014. State tax rates range from 6% in Missouri to combined state-local rates exceeding 40% in some California jurisdictions, creating significant price disparities that influence illicit market competition.

Federal Rescheduling Efforts and Tax Implications

The Drug Enforcement Administration announced on May 16, 2024, that it would initiate rulemaking to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act, following a recommendation from the Department of Health and Human Services. The proposed rule, published in the Federal Register on August 29, 2024, triggered a 60-day public comment period that generated more than 43,000 submissions—the most in DEA history for a scheduling action. Schedule III rescheduling would not legalize cannabis federally but would eliminate 280E tax penalties, allowing businesses to deduct ordinary business expenses. The Joint Committee on Taxation estimated in September 2024 that rescheduling would reduce federal tax revenue by $2.3 billion over ten years, as cannabis businesses would pay lower effective tax rates. However, rescheduling would not create a new federal excise tax framework—that would require congressional legislation.

Congressional Legalization Proposals

Multiple legalization bills have been introduced in Congress since 2019, each with different tax structures. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, passed by the House of Representatives on April 1, 2022, by a vote of 220-204, proposed a 5% federal excise tax escalating to 8% over three years, with revenue dedicated to community reinvestment and expungement programs. The bill died in the Senate without a vote. The Cannabis Administration and Opportunity Act (CAOA), introduced by Senate Majority Leader Chuck Schumer on July 21, 2021, proposed a three-tiered federal excise tax based on THC content and product type, starting at 10% and escalating to 25% over five years. The bill included provisions for small business tax credits and social equity programs but has not advanced to a floor vote as of August 2026. The States Reform Act, introduced by Representative Nancy Mace on November 15, 2021, proposed a 3% federal excise tax with revenue allocated to law enforcement, small business administration, and veterans' healthcare. The bill represented a Republican-sponsored alternative to Democratic proposals but similarly failed to advance beyond committee.

Key Players in Federal Cannabis Tax Policy

Yale Program on Addiction Medicine

The Yale Program on Addiction Medicine, part of the Yale School of Medicine, published the $111 billion revenue projection in August 2026 under the direction of Dr. Deepa Camenga, an associate professor specializing in substance use policy. The study employed econometric modeling based on state-level tax collection data from 24 jurisdictions, adjusted for federal population scale, interstate commerce effects, and various tax rate scenarios. The research team included economists from Yale's Department of Health Policy and Management who previously analyzed tobacco and alcohol excise tax impacts.

Congressional Budget Office

The Congressional Budget Office provides official revenue estimates for proposed legislation, including cannabis bills. In 2021, CBO estimated that the MORE Act would generate $8.1 billion in federal revenue over ten years, assuming a 5-8% excise tax and 50-state legalization by year five. The estimate included $3.1 billion in excise taxes and $5 billion in additional income tax revenue from newly legal businesses. CBO's methodology differs from academic projections by incorporating dynamic scoring that accounts for behavioral changes and enforcement costs.

Drug Enforcement Administration

The Drug Enforcement Administration maintains authority over cannabis scheduling under the Controlled Substances Act, 21 U.S.C. § 801 et seq. Administrator Anne Milgram, appointed in 2021, oversees the ongoing rescheduling review that could eliminate 280E tax burdens even without full legalization. The DEA's decision on rescheduling, expected in late 2026 or early 2027 following administrative law judge hearings, will directly impact federal tax revenue by changing the tax treatment of cannabis businesses.

Internal Revenue Service

The Internal Revenue Service enforces 26 U.S.C. § 280E, which prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. IRS guidance, including Chief Counsel Advice 201504011, requires cannabis businesses to calculate cost of goods sold narrowly, disallowing deductions for marketing, rent, and administrative expenses. The agency collected an estimated $1.8 billion in additional tax revenue from cannabis businesses in fiscal year 2023 due to 280E, according to analysis by cannabis accounting firm Green Growth CPAs. Legalization would eliminate this revenue source while creating new excise tax streams.

Multi-State Operators and Industry Groups

The Cannabis Trade Federation, National Cannabis Industry Association, and U.S. Cannabis Council represent licensed operators in federal policy debates. These organizations advocate for tax structures that balance revenue generation with market competitiveness against illicit sales. Curaleaf, the largest U.S. cannabis company by revenue with $1.4 billion in 2023 sales, has publicly supported federal excise taxes below 10% to avoid pricing cannabis out of the legal market. Trulieve, the dominant operator in Florida with $1.2 billion in 2023 revenue, has emphasized the importance of 280E relief in improving industry profitability and tax compliance.

Legal and Regulatory Framework for Federal Cannabis Taxation

Federal cannabis taxation requires congressional legislation to establish excise tax rates, collection mechanisms, and revenue allocation, as the Controlled Substances Act currently prohibits commerce rather than regulating it through taxation. The constitutional basis for federal cannabis taxation derives from Article I, Section 8, Clause 1 of the U.S. Constitution, which grants Congress the power to "lay and collect Taxes, Duties, Imposts and Excises." The Supreme Court upheld broad federal taxing authority in United States v. Sanchez (1950) and Gonzales v. Raich (2005), the latter affirming federal commerce power over intrastate cannabis cultivation. Current law provides no framework for legal federal cannabis taxation. The Controlled Substances Act, 21 U.S.C. § 801-971, criminalizes cannabis manufacture, distribution, and possession, making taxation impossible without prior legalization or rescheduling. Section 280E of the Internal Revenue Code, 26 U.S.C. § 280E, explicitly prohibits tax deductions for businesses trafficking in Schedule I or II substances, creating punitive effective tax rates but not establishing an excise tax regime. Proposed legislation would create federal excise taxes modeled on alcohol and tobacco frameworks. The Federal Alcohol Administration Act, 27 U.S.C. § 201 et seq., establishes per-gallon excise taxes collected at the production level, ranging from $2.70 per wine gallon for distilled spirits to $0.16 per barrel for beer under 31 gallons. The Alcohol and Tobacco Tax and Trade Bureau, a division of the Department of the Treasury, administers collection through a permit and bonding system. Cannabis tax proposals typically employ ad valorem taxes (percentage of price) rather than per-unit taxes, though some bills include hybrid approaches. The MORE Act's 5-8% ad valorem tax would apply at the point of retail sale or removal from the production facility, whichever occurs first. The CAOA's tiered structure would impose different rates based on THC potency, with higher taxes on concentrates and edibles than flower—a structure intended to discourage high-potency product consumption. Revenue allocation varies by proposal. The MORE Act dedicates excise tax revenue to the Opportunity Trust Fund, which would finance job training, reentry services, legal aid for expungement, and small business loans in communities disproportionately impacted by cannabis prohibition. The States Reform Act allocates revenue to the Small Business Administration (35%), Community Reinvestment Grant Program (40%), law enforcement (10%), and FDA regulatory costs (15%). Banking and payment processing remain critical implementation challenges. The Bank Secrecy Act, 31 U.S.C. § 5311 et seq., requires financial institutions to file Suspicious Activity Reports for transactions involving proceeds from illegal activity. FinCEN guidance issued in 2014 provides a safe harbor for banks serving state-legal cannabis businesses, but most major banks decline cannabis accounts due to federal illegality. The SAFE Banking Act, passed by the House seven times since 2019 but never by the Senate, would prohibit federal banking regulators from penalizing institutions that serve legal cannabis businesses. Without banking access, tax collection becomes operationally complex, as many cannabis businesses currently pay state taxes in cash.

State-by-State Tax Revenue Breakdown

The 24 adult-use states generated $4.2 billion in combined cannabis tax revenue in 2023, with California, Illinois, and Washington accounting for 48% of total collections.

State	Legalization Date	Tax Rate	2023 Revenue	Cumulative Revenue
California	January 1, 2018	15% excise + cultivation tax	$1.29 billion	$5.8 billion
Illinois	January 1, 2020	10-25% tiered by product	$561 million	$1.9 billion
Washington	July 8, 2014	37% excise	$559 million	$3.7 billion
Colorado	January 1, 2014	15% excise + 15% retail	$448 million	$2.1 billion
Michigan	December 1, 2019	10% excise	$411 million	$1.3 billion
Massachusetts	November 20, 2018	10.75% excise + 6.25% sales	$237 million	$1.1 billion
New Jersey	April 21, 2022	Variable by price tier	$173 million	$312 million
Arizona	January 22, 2021	16% excise	$168 million	$542 million

California

California operates the largest legal cannabis market in the United States, with $5.3 billion in retail sales in 2023. The state imposes a 15% cannabis excise tax on retail sales plus a cultivation tax of $10.08 per ounce of flower and $3.00 per ounce of trim, collected at the distributor level. Local jurisdictions can add taxes up to 15%, resulting in combined rates exceeding 40% in cities like Los Angeles and San Francisco. Despite high tax rates, California collected $1.29 billion in fiscal year 2022-2023, below projections due to illicit market competition estimated at 50-60% of total consumption. The state eliminated the cultivation tax effective July 1, 2024, to improve legal market competitiveness.

New York

New York launched adult-use sales on December 29, 2022, following legalization via the Marihuana Regulation and Taxation Act signed March 31, 2021. The state imposes a 13% excise tax plus a potency-based tax of $0.005 per milligram of THC for flower, $0.008 per milligram for concentrates, and $0.03 per milligram for edibles. First-year revenue totaled $87 million, below initial projections of $150 million due to slow licensing and continued illicit market dominance. The Office of Cannabis Management issued only 123 retail licenses in the first year, compared to 1,400 applications, creating supply constraints that limited tax revenue.

Florida

Florida voters will decide on adult-use legalization via Amendment 3 on the November 2024 ballot, requiring 60% approval. The proposed amendment does not specify tax rates, leaving that determination to the legislature. If approved, Florida's medical cannabis market—the third-largest in the nation with $2.1 billion in 2023 sales—would transition to adult-use, potentially generating $450-600 million annually in state tax revenue according to estimates by the Florida Policy Institute. Trulieve, which controls approximately 50% of Florida's medical market, contributed $95 million to the legalization campaign.

Texas

Texas maintains prohibition of adult-use cannabis, with possession of any amount remaining a criminal offense. The state operates a limited medical program restricted to low-THC products for specific conditions. Multiple legalization bills have been introduced in the Texas Legislature, including HB 447 in 2023, which proposed a 10% excise tax projected to generate $1.1 billion annually. The bill died in committee without a floor vote. Polling by the University of Texas in June 2026 showed 68% support for legalization among Texas voters, but Republican legislative leadership has blocked reform efforts.

Market and Business Implications of Federal Tax Revenue

Federal legalization would eliminate 280E tax burdens that currently cost cannabis operators $1.8 billion annually while creating new excise tax obligations that could total $4-5 billion per year under proposed legislation. Multi-state operators face effective tax rates of 70-80% under current law due to Section 280E, which disallows deductions for rent, salaries, marketing, and other ordinary business expenses. Curaleaf reported $1.4 billion in revenue for fiscal year 2023 but paid $147 million in income taxes—an effective rate of 10.5% on revenue rather than profit—due to limited deductibility. The company's adjusted EBITDA of $311 million would have supported income tax liability of approximately $65 million at standard corporate rates, meaning 280E added $82 million in tax burden. Rescheduling to Schedule III would eliminate 280E immediately, improving operator margins by 30-40 percentage points according to analysis by Viridian Capital Advisors. Green Thumb Industries estimated in its 2024 annual report that 280E relief would increase net income by $95 million annually, improving cash flow for expansion and debt service. However, rescheduling would not address banking access, interstate commerce restrictions, or FDA regulatory oversight that would accompany Schedule III classification. Full federal legalization with excise taxes would create a different financial landscape. A 10% federal excise tax on the $30 billion U.S. legal cannabis market would generate $3 billion annually, distributed among operators, consumers, and state governments depending on tax incidence. Economic research on alcohol and tobacco excise taxes suggests that 60-80% of tax burden falls on consumers through higher prices, with the remainder absorbed by producers through lower margins. Price compression represents a critical risk factor. Legal cannabis prices have declined 50-70% in mature markets like Colorado and Washington as supply has expanded and competition has intensified. Colorado's average retail price per ounce fell from $296 in 2015 to $131 in 2023, reducing per-transaction tax revenue even as unit sales increased. Federal legalization would accelerate price compression by enabling interstate commerce, allowing low-cost producers in California and Oregon to ship product to high-price markets in New York and Illinois. The Yale study projects that federal legalization would reduce average retail prices by 35-45% within five years, requiring higher tax rates or unit-based taxes to maintain revenue targets. Banking access would transform capital markets for cannabis operators. The industry currently relies on private equity, venture capital, and high-interest debt due to limited access to traditional bank loans and public equity markets. Curaleaf pays 9-12% interest on senior secured debt, compared to 4-6% for similarly sized consumer packaged goods companies. SAFE Banking passage would reduce borrowing costs by 300-500 basis points, saving large operators $20-40 million annually in interest expense and enabling expansion through cheaper capital. Interstate commerce would consolidate the industry rapidly. Currently, 37 states require vertical integration, forcing operators to cultivate, process, and retail within state borders. Federal legalization would eliminate these barriers, allowing efficient producers to achieve economies of scale. Analysts at Cowen project that interstate commerce would reduce the number of viable cultivators from approximately 8,000 currently to fewer than 500 within a decade, mirroring consolidation patterns in the beer and wine industries following Prohibition repeal.

What Experts Say About Federal Cannabis Tax Revenue

Economists, policy analysts, and industry leaders offer divergent perspectives on optimal federal tax rates, revenue reliability, and allocation priorities. Dr. Rosalie Pacula, senior economist at the RAND Corporation and co-director of the RAND Drug Policy Research Center, has argued that cannabis excise taxes should be structured to minimize public health harms rather than maximize revenue. In testimony before the Senate Finance Committee in March 2025, Pacula recommended potency-based taxes that discourage high-THC products, similar to alcohol taxation that increases with proof. She cited research showing that THC concentrations in cannabis flower have increased from 4% in 1995 to 17% in 2023, with concentrates reaching 80-90% THC, raising concerns about cannabis use disorder and psychosis risk in heavy users. Pat Oglesby, founder of the Center for New Revenue and former chief tax counsel for the Senate Finance Committee, has advocated for weight-based or potency-based taxes rather than ad valorem approaches. According to Oglesby's analysis published in Tax Notes in July 2024, ad valorem taxes create perverse incentives for producers to increase potency to maximize revenue per tax dollar, while weight-based taxes encourage lower-potency products. He proposed a federal tax of $50 per ounce of flower and $200 per ounce of concentrate, projected to generate $4.8 billion annually while discouraging high-potency product proliferation. The Cannabis Trade Federation, representing 1,200 licensed businesses, released a white paper in May 2026 recommending federal excise taxes not exceed 7% to avoid pricing legal cannabis above illicit market rates. The analysis noted that California's combined state-local tax rates of 35-45% have sustained a thriving illicit market estimated at $8 billion annually, compared to $5.3 billion in legal sales. Federation CEO Diane Czarkowski stated in a press release that excessive taxation "undermines the core policy goals of legalization—eliminating the illicit market and protecting public health through regulated products." State-level revenue data supports concerns about tax rate sensitivity. Washington reduced its cannabis tax rate from 44% to 37% in 2015 after initial collections fell below projections, subsequently seeing revenue increase 23% as legal market share expanded. Oregon, which imposes a 17% state tax, has seen steady revenue growth averaging 12% annually since 2016, suggesting moderate tax rates support compliance and market growth. Jonathan Caulkins, professor of operations research and public policy at Carnegie Mellon University, has cautioned that federal revenue projections often overestimate collections by failing to account for tax evasion, price compression, and interstate smuggling. In a 2025 article in the Journal of Policy Analysis and Management, Caulkins noted that tobacco tax evasion costs states $5.1 billion annually, approximately 15% of potential revenue, and predicted similar evasion rates for cannabis absent robust enforcement. He recommended federal cannabis taxation include track-and-trace requirements, tax stamps, and interstate cooperation agreements to minimize revenue leakage.

What's Next for Federal Cannabis Tax Policy

The Drug Enforcement Administration's rescheduling decision, expected in late 2026 or early 2027, will determine whether 280E relief occurs before comprehensive legalization, while congressional action on legalization bills remains uncertain heading into the 2026 midterm elections. The DEA's administrative law judge hearings on cannabis rescheduling commenced in December 2024 and concluded in June 2026, with a final recommendation expected by November 2026. If the DEA adopts the recommendation to reschedule cannabis to Schedule III, the rule would take effect 30 days after publication in the Federal Register, immediately eliminating 280E tax penalties. However, rescheduling would not create federal excise tax authority or legalize cannabis—those changes require congressional legislation. In Congress, the MORE Act has been reintroduced in the 119th Congress as HR 2015, with 87 cosponsors as of August 2026. The bill faces uncertain prospects in a closely divided House and Senate, where Republican leadership has historically opposed legalization. Senate Majority Leader Chuck Schumer has indicated that cannabis legislation remains a priority, but competing legislative priorities including budget reconciliation and appropriations bills may delay floor consideration until 2027. The SAFE Banking Act, reintroduced as S. 1323, has 42 Senate cosponsors including nine Republicans, suggesting possible bipartisan support. However, previous attempts to attach SAFE Banking to must-pass legislation including the National Defense Authorization Act have failed due to opposition from Senate Banking Committee leadership. Some advocates have proposed a compromise approach that would combine SAFE Banking with modest federal excise taxes and enhanced state enforcement funding, potentially attracting broader support. State-level legalization momentum continues, with ballot initiatives expected in Florida, Nebraska, North Dakota, and South Dakota in November 2024. If Florida approves Amendment 3, the state would become the 25th adult-use jurisdiction and the largest market by population, potentially adding $500-600 million in annual state tax revenue. Success in Florida could pressure neighboring states including Georgia, Alabama, and Tennessee to consider legalization to avoid cross-border sales and revenue loss. International developments may influence U.S. policy. Germany launched adult-use legalization on April 1, 2024, becoming the largest European market, while the United Kingdom is conducting a comprehensive cannabis policy review expected to conclude in late 2026. If major U.S. allies adopt legalization frameworks, political pressure for federal reform may intensify. The 2026 midterm elections will reshape the congressional landscape and potentially alter legalization prospects. Polling by Gallup in May 2026 showed 71% of Americans support cannabis legalization, including 52% of Republicans, suggesting growing political viability. However, legalization remains a lower-priority issue for most voters compared to economic policy, healthcare, and immigration, limiting its influence on electoral outcomes. Budget reconciliation represents a potential legislative vehicle for cannabis tax policy. If a party controls both chambers of Congress and the presidency after 2026, cannabis excise taxes could be included in a reconciliation bill requiring only a simple majority in the Senate. This approach was used for tobacco tax increases in the 2009 Children's Health Insurance Program reauthorization, suggesting a precedent for cannabis taxation through budget procedures.

Further Reading and Primary Sources

• Yale Program on Addiction Medicine, "Fiscal and Economic Impacts of Federal Cannabis Legalization" (August 2026) — full study available at medicine.yale.edu/addiction
• Congressional Budget Office, "Budgetary Effects of H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act" (March 2021) — www.cbo.gov
• Drug Enforcement Administration, "Schedules of Controlled Substances: Rescheduling of Marijuana" [Proposed Rule], 89 Fed. Reg. 44,597 (August 29, 2024) — www.federalregister.gov
• Internal Revenue Service, Chief Counsel Advice 201504011, "Application of Section 280E to Medical Marijuana Dispensaries" (January 23, 2015) — www.irs.gov
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — full text at uscode.house.gov
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — full text at uscode.house.gov
• California Department of Tax and Fee Administration, Cannabis Tax Revenue Reports — www.cdtfa.ca.gov/cannabis
• Colorado Department of Revenue, Marijuana Tax Data — cdor.colorado.gov/data-and-reports
• Washington State Liquor and Cannabis Board, Marijuana Revenue Reports — lcb.wa.gov/records/frequently-requested-lists
• RAND Corporation, "Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions" (2015) — www.rand.org
• Tax Foundation, "How High Are Cannabis Taxes in Your State?" (updated quarterly) — taxfoundation.org
• National Conference of State Legislatures, "State Medical Cannabis Laws" (updated monthly) — www.ncsl.org
• Marijuana Policy Project, "State-by-State Cannabis Policy Reform" — www.mpp.org/states
• FinCEN, "BSA Expectations Regarding Marijuana-Related Businesses" (February 14, 2014) — www.fincen.gov
• U.S. Department of Health and Human Services, "Recommendation to Reschedule Marijuana" (August 2023) — www.hhs.gov